上药康德乐(重庆)医药有限公司

SPH KDL Health (Chongqing) Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") is a holding subsidiary of SPH Group, which is managed by the State-owned Assets Supervision and Administration Commission of Shanghai Municipality. The parent company, Shanghai Pharma Group, is a leading enterprise in the pharmaceutical industry in China. Its business covers the entire industrial chain of pharmaceutical research and development, manufacturing, distribution, retail, and investment. In 2020, it entered the list of the world's top 500 companies, ranking 473, and ranked 57 among the top 500 listed enterprises in China (A+H). It is also ranked 48th globally in the pharmaceutical industry, 24th globally in pharmaceutical brands, and among the top three in the Chinese pharmaceutical industry. In 2019, the company achieved an operating revenue of 186.6 billion yuan, ranking 43rd among the top 500 Chinese manufacturing enterprises, 93rd in the "China Brand Development Index" 100 list by the People's Daily, and 25th in global pharmaceutical brand value.

The Chongqing company was established in 1993, formerly known as Chongqing Pharmaceutical Development Company under the Chongqing Pharmaceutical Administration, with a registered capital of 50 million yuan, located at No. 137 Keyuan Second Road, Jiulongpo District, with 115 employees. The company is dedicated to diversified supply chain services such as drugs and medical devices and is a mainstream pharmaceutical circulation enterprise in Chongqing. It ranks second in the transaction and distribution amount of medical institutions in the Chongqing Drug Exchange. It is authorized by over a thousand manufacturers and can deliver more than 15,000 product specifications. The company is also the only national pharmaceutical circulation enterprise in Jiulongpo District and has been selected as one of the designated distribution members of the Jiulongpo District consortium for two consecutive terms, undertaking the security supply of nearly a thousand product specifications of medicines in 22 medical institutions in Jiulongpo District.

The company has received titles such as "Vice Chairman Unit of Chongqing Pharmaceutical Industry Association," "Vice Chairman Unit of Chongqing Medical Insurance Research Association," "Vice Chairman Unit of Chongqing Jiulongpo Pharmaceutical Chamber of Commerce," and "Jiulongpo District Model and Demonstration Wholesale Enterprise." It has been inspected and guided by the State Food and Drug Administration, district government, and district People's Congress multiple times.

In 2020, the company achieved an operating revenue of 1.56 billion yuan (including tax) and paid taxes of 16.69 million yuan. During the 2020 pandemic, the company was designated as a "Chongqing Epidemic Prevention Material Reserve Unit" and contributed positively to the city's fight against the epidemic, earning the title of "Special Contribution Enterprise for Epidemic Resistance."

The company will continue to rely on the strong headquarters resources of SPH Group, adhering to a customer-centric service philosophy, compliance, integrity, and transparent management requirements, to better fulfill its responsibilities in serving medical reform and society, safeguarding people's livelihood, and serving the vast number of patients in the area, making new contributions to the medical and health reform of Jiulongpo District.